Daiichi Sankyo, a global pharmaceutical company, is seeking a fully cell‑free, in vitro technology capable of synthesizing and amplifying plasmid DNA without relying on E. coli. 
Approaches of Interest:
<ul>
<li>Recombination Assembly Methods
<ul>
<li>Methods that can reproduce a highly efficient homologous recombination system of microorganisms in vitro, resulting in seamless DNA ligation </li>
<li>Methods that can correctly assemble and integrate 50 or more DNA fragments at once via a timely (less than 30 minute) isothermal reaction</li>
</ul>
</li>
<li>Replication Cycle Reaction Methods
<ul>
<li>Able to mimic the E. coli genome replication system in vitro using a reconstituted set of proteins for amplification</li>
<li>Amplification of a single circular DNA molecule in a time-effective manner</li>
<li>Enables amplification of long circular DNA molecules exceeding 10 kb in vitro</li>
<li>Can achieve high application accuracy, exceeding that of traditional PCR</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Replication systems in E. coli</li>
<li>Technologies costing over ten times more than conventional E. coli culture methods</li>
<li>Technologies requiring dedicated equipment with initial investments exceeding 100 million yen</li>
<li>Methods taking over one week per plasmid to generate</li>
<li>Opportunities relating to minicircle DNA or mRNA</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Daiichi Sankyo is seeking basic research accompanied by experimental verification</li>
<li>Methods must be established</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking a fully cell‑free, in vitro technology capable of synthesizing and amplifying plasmid DNA without relying on E. coli. 

Cell-free Synthesis of Transfection-grade Plasmid DNA for Automated Processing

Daiichi Sankyo, a global pharmaceutical company, is seeking disease models of macular degeneration-specifically atrophic age-related macular degeneration (AMD) and Stargardt disease-that have high translational potential for clinical use. To this end, they are seeking disease models that are induced by fundamental pathological mechanisms known in AMD or that have demonstrated responsiveness to existing AMD therapies
Approaches of Interest:
<ul>
<li>In vitro and in vivo disease models that are close to human disease states in terms of disease state inducers, gene expression, and pathology</li>
<li>The model should meet at least two of the following criteria:
<ul>
<li>It is induced by factors that are strongly associated with AMD</li>
<li>It demonstrates concordance with human pathology, such as the development of CNV or localized RPE atrophy</li>
<li>It shows responsiveness to agents that have exhibited efficacy signals in AMD clinical trials, including complement inhibitors</li>
</ul>
</li>
<li>Research to evaluate the efficacy of drugs using above AMD and Stargardt disease models </li>
</ul>
Out of Scope:
<ul>
<li>Models that are not applicable to age-related macular degeneration or Stargardt disease</li>
<li>In silico and AI powered models</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities from basic research to preclinical research are within scope</li>
<li>Opportunities with animal models or in vitro RPE cell models are of highest interest</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking disease models of macular degeneration that are induced by fundamental pathological mechanisms known in AMD or that have demonstrated responsiveness to existing AMD therapies.

Seeking Novel Disease Models of Macular Degeneration

Nissan Chemical Corporation, a forerunner in chemical innovations, is seeking novel ASO and siRNA therapeutics for CNS and liver diseases. They are especially interested in therapeutics that are facing challenges with toxicity, stability, and efficacy, which may be able to leverage their proprietary platform which incorporates 2’-O-[2-(N-methylcarbamoyl)ethyl] (MCE)-modified nucleotides to overcome these challenges. 
Approaches of Interest: 
<ul>
<li>Diseases of interest include rare and neurodegenerative CNS diseases (e.g. ALS, inherited ataxias), rare metabolic and liver fibrosis diseases (e.g. MASH, PBC, PSC), and conditions caused by hepatocyte-secreted proteins (e.g. complement-related disorders, hemophilia) </li>
<li>Therapeutics for CNS disorders could be delivered locally (e.g. via intrethecal or intracerebroventricular injection) or systemically with BBB-penetrating technologies. For liver disorders, therapeutics should be administered systemically and act within hepatocytes. </li>
<li>Therapeutics that work through gene silencing are highest priority </li>
<li>Novel gene and protein targets for diseases of interest are in scope </li>
</ul>
Out of Scope: 
<ul>
<li>Ultra-rare CNS and liver diseases (i.e. less than 1000 patients globally) </li>
<li>Therapeutics that act via gene upregulation </li>
<li>Other nucleic acid therapeutics (e.g. aptamers, miRNA) </li>
<li>Novel chemically modified nucleic acid platforms </li>
</ul>
Developmental Stages of Interest: 
<ul>
<li>Opportunities from basic research to late preclinical are in scope, provided there is in vivo proof of concept </li>
</ul>
Submission Information and Opportunity for Collaboration 
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Nissan Chemical Corporation is looking to establish research collaborations with partners who would be able to leverage their MCE-ASO/siRNA platform, which incorporates MCE-modified nucleotides. This unique chemistry is engineered to provide enhanced nuclease resistance, minimize hepatotoxicity and neurotoxicity, and improve knockdown efficacy and durability in vivo. They may also consider strategic investment.

Nissan Chemical Corporation is seeking novel antisense oligonucleotide and siRNA therapeutics in development for CNS and liver disorders that are facing challenges with toxicity, stability, and efficacy.

ASO and siRNA Therapeutics for CNS and Liver Disorders 

AstraZeneca is seeking datasets or physical/virtual libraries of macrocyclic peptides that can help map and model the property space required for oral and cell permeable macrocyclic peptides. They particularly welcome: 
<ul>
<li>Annotated in vitro/vivo datasets describing permeability, oral bioavailability, enzymatic stability or other relevant properties of peptide macrocycles—including both proprietary and published collections</li>
<li>Libraries of macrocyclic peptides which are suitable for screening, ideally with reference activity which would enable AI-led property mapping and predictive modelling. Physical compound sets are preferred but virtual libraries may be accepted for use once training datasets have been established</li>
<li>Novel or proprietary methods for predicting, quantifying, or modelling the physicochemical space that governs permeability and oral absorption in macrocyclic peptides</li>
</ul>
Out of scope: Proposals that are hypothetical, lack experimental feasibility, or involve low-throughput experimental or predictive modelling approaches that are not scalable for parallel evaluation of large compound sets will be given a lower priority.
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Submissions should either provide experimental proof-of-concept, published evidence, or actionable approaches for generating datasets or screening tools that address these key parameters. Solutions that enable parallel evaluation of multiple macrocyclic peptides, or which deliver mechanistic or predictive insights into the determinants of oral and cell permeability, are particularly encouraged. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly. Details about the collaboration benefits can be found in the proposal form.

AstraZeneca is seeking datasets or physical/virtual libraries of macrocyclic peptides that can help map and model the property space required for oral and cell permeable macrocyclic peptides. 

AI/ML-ready Datasets for Peptide Permeability & Oral Bioavailability or Macrocyclic Peptide Screening Libraries to Enable Oral, Cell-permeable Macrocycle Design

AstraZeneca aims to build a world class peptide discovery platform, combining phage and mRNA display technologies and amenable to the incorporation of a wide variety of non-canonical amino acids (ncAAs) in those display systems, from ncAAs capable of forming covalent bonds to enable new chemistries in peptides, such as cyclization, to ncAAs which can introduce novel physicochemical properties, such as altered hydrophobicity, charge, or backbone rigidity, to manipulate peptide solubility, cellular uptake, or overall structural dynamics.
The team at AstraZeneca is seeking solutions for the efficient incorporation of ncAAs in phage and/or mRNA display systems that allow for thioether macrocycle cyclisation and/or efficient incorporation of a range of amino acids. Proposed solutions to this challenge should meet the following solution requirements to be considered for funding by AstraZeneca. The selected collaborator will need to provide AstraZeneca with reagents allowing for at least one of the following: 
<ul>
<li>Efficient incorporation of ncAAs allowing for thioether macrocycle cyclisation in a phage display system. This should go beyond the simple use of evolved tRNA synthetases and overcome some of the limitations of stop codon reprogramming</li>
<li>Efficient incorporation of ncAAs allowing for thioether macrocycle cyclisation in an mRNA display/cell free protein expression system</li>
<li>Incorporation of other types of ncAA such as but not limited to N-methylated amino acids, fluorosulphate-amino acid, Aib, in an mRNA display/cell free protein expression system</li>
</ul>
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. 
Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly.

AstraZeneca is seeking solutions for the efficient incorporation of ncAAs in phage and/or mRNA display systems that allow for thioether macrocycle cyclisation and/or efficient incorporation of a range of amino acids.

Non-canonical Amino Acids for in vitro Display Systems

AstraZeneca is seeking screening assays, or predictive models relevant to oral bioavailability and/or cell permeability of macrocyclic peptides that can help map and model the property space required for oral and cell-permeable macrocyclic peptides. They particularly welcome: 
<ul>
<li>High-throughput screening assays (in vitro and ex vivo) or advanced in silico platforms for quantifying key properties relevant to oral bioavailability and/or cellular permeability of macrocyclic peptides</li>
<li>Novel or proprietary methods for predicting, quantifying, or modelling the physicochemical space that governs permeability and oral absorption in macrocyclic peptides</li>
<li>Annotated data generated from these screening methods</li>
</ul>
The selected collaborator will receive at least 8 benchmark compounds to confirm permeability ranking in a blinded study. Following screening, compounds will be unblinded for the collaborator and available to use freely. 
Out of scope: Proposals that are hypothetical, lack experimental feasibility, or involve low-throughput experimental or predictive modelling approaches that are not scalable for parallel evaluation of large compound sets will be given a lower priority. 
Submission and Programme Information and Opportunity for Collaboration
AstraZeneca invites applications from both academic and biotech organizations. Applicants should complete the <a href="">proposal form</a> which should contain a brief, non‑confidential overview of your proposal, including a workplan, approximate budgetary requirements, desired outcomes, and background on your research group. To submit your proposal, please visit the <a href="">Inpart website</a>, register, and submit your application form under the appropriate campaign. Proposed collaborations or data contributions should either provide experimental proof-of-concept, published evidence, or actionable approaches for generating datasets or screening tools that address these key parameters. Solutions that enable parallel evaluation of multiple macrocyclic peptides, or which deliver mechanistic or predictive insights into the determinants of oral and cell permeability, are particularly encouraged. Further details on the solution criteria can be found in the proposal form.
AstraZeneca’s CoSolve challenge is a global Open Innovation programme seeking collaborators with innovative solutions to real research challenges. These challenges lie within the company’s R&amp;D research focus areas and require solutions that are immediately translatable. Collaborators are sought who can bring innovative ideas that can be rapidly translated into tangible solutions. Working together, these ideas could help shape the development and delivery of new therapies and bring them to patients sooner. Applications that are of interest will be selected to participate in the virtual Challenge Week - an intensive week where applicants will pitch their ideas and work with AstraZeneca scientists to transform their idea into a workplan. For selected winners from the challenge week, a <a href="">collaboration agreement</a> will be put in place with specified milestones and the winning projects can begin quickly. Details about the collaboration benefits can be found in the proposal form.

AstraZeneca is seeking established screening assays relevant to oral bioavailability and/or cell permeability of macrocyclic peptides that can help map and model the property space required for oral and cell-permeable macrocyclic peptides. 

High Throughput Screening Assays to Map Macrocyclic Peptide Permeability and Stability Properties

ICL Group, a leading producer of phosphoric acid for chemical manufacturing, is seeking novel and mature solutions to remove or treat organic impurities from the phosphoric acid production process. Approaches that target all stages of the manufacturing process are in scope, including mining and beneficiation of phosphate rock, acid production, and post-processing, with the earlier stages being highest priority. Solutions should reduce the organic content in merchant grade phosphoric acid to industry-acceptable levels. 
Approaches of Interest:
<ul>
<li>The impurities of highest interest are organic impurities, mainly humic acid and fulvic acid</li>
<li>Solutions need to be able to work in harsh conditions and be able to withstand dust, fluorine, high temperatures, and high acidity</li>
<li>Solutions that are cost effective, scalable for large industrial plants, and are environmentally sustainable are of highest priority </li>
<li>Processes that use catalysts are in scope </li>
</ul>
Out of Scope:
<ul>
<li>Approaches that aren’t cost effective at industrial scale </li>
<li>Approaches that can’t withstand the harsh operational conditions (e.g. UV-based) </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities must have at least pilot-scale proof of concept (TRL 5), better to have even higher as the idea is to implement the solution quickly and initiate the industrial project by Q4, 2026 </li>
<li>Priority will be given to later stage solutions with demonstrated efficacy in operational environments </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should provide a clear description of the technology and proof-of-concept data. Submissions that also include cost estimates will be prioritized. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, service agreements, or ongoing collaborations.

ICL Group is seeking novel solutions to remove organic impurities, such as humic acid and fulvic acid, from any stage of phosphoric acid production.

Reducing Organic Impurities in Phosphoric Acid Production

Daiichi Sankyo is is seeking opportunities focused on novel drug delivery platforms. 
1. Drug delivery technologies for CNS drugs
<ul>
<li>Opportunities enabling systemic delivery of CNS‑targeted drugs (e.g., oligonucleotides) across the blood‑brain barrier for psychiatric and neurodegenerative diseases are of interest, provided a clearly defined mechanism of BBB penetration is demonstrated</li>
<li>Basic research through to preclinical research is within scope. In vivo distribution data, cell-type-specific drug distribution data (e.g., neurons, astrocytes, oligodendrocytes, microglia), and an in vitro cell assay system to quantitatively evaluate BBB penetration of the delivery system are all desirable</li>
<li>Opportunities related to well defined pathways including TfR, CD98, or IGF1R are out of scope. Additionally, non‑selective delivery methods (e.g., ultrasound, nanoparticles, liposomes), approaches with unresolved scalability and COG (cost of goods) challenges (such as engineered nanoparticles and extracellular vesicles), and nose‑to‑brain delivery strategies are out of scope</li>
</ul>
2. Eye‑drop delivery system for small molecules, peptides, and antibodies to retinal and choroidal tissue in retinal diseases
<ul>
<li>Versatile delivery systems not restricted to specific compounds, with retinal or choroidal exposure confirmed by in vivo studies are of interest (data from rabbits or pigs preferred)</li>
<li>Basic research through to preclinical research is within scope. Desirable data include efficacy in animal models of retinal diseases, stability of the eye‑drop solution, and toxicity assessments for the cornea or other anterior segment tissues</li>
</ul>
3. Technologies capable of selective tumor tissue-targeted delivery
<ul>
<li>Technologies must demonstrate enhanced accumulation in tumor tissue (comprising tumor cells, fibroblasts, stromal and immune cells) with reduced liver and kidney uptake, enable intracellular delivery of oligonucleotides or proteins, and be supported by robust, well‑established manufacturing processes</li>
<li>Technologies capable of selectively delivering to tumor-specific environments (e.g. pH, hypoxia, etc.) are of high interest</li>
<li>Research ranging from basic studies (with supporting experimental data) through Phase II is within scope</li>
<li>Out of scope are approaches limited to organ‑specific targeting, delivery methods such as viruses and nanoparticles, and technologies that rely solely on the Enhanced Permeability and Retention effect</li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. Daiichi Sankyo is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, MTA and research collaborations.

Daiichi Sankyo is seeking drug delivery platforms for CNS drugs that cross the blood–brain barrier, eye‑drop systems targeting retinal and choroidal tissues, and technologies enabling selective tumor tissue targeting.

Drug Delivery Platforms: Novel BBB-penetrating Systems, Ocular Eye-drop Systems, and Tumor Tissue-targeted Intracellular Approaches

Daiichi Sankyo, a global pharmaceutical company, is seeking research related to the identification and mechanistic characterization of extracellular proteases whose inhibition suppresses disease onset or progression. 
Approaches of Interest:
<ul>
<li>Opportunities related to immune, cardiometabolic or ophthalmic disorders are of highest priority </li>
<li>Systemic inhibition of the protease is anticipated to carry little to no toxicity, though this does not apply to protease inhibition for ophthalmic diseases</li>
<li>The contribution of the protease to the disease pathology should have been validated by in vivo or ex vivo experiments involving knockout (KO) or knockdown (KD) of the protease </li>
</ul>
Out of Scope:
<ul>
<li>Target diseases exclude cancer and all infectious diseases, including COVID‑19 and HIV </li>
<li>Studies on the development of any modalities for specific protease inhibition </li>
<li>Opportunities related to intracellular proteases </li>
<li>Drug discovery and development platforms</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Basic research—provided it is supported by wet‑lab data—through to preclinical research is within scope </li>
<li>Proposals should include in vivo or ex vivo data, preferably using human-relevant disease models, enabling the verification of the contribution of the protease to the disease </li>
<li>Proposals should provide a clear outline of the subsequent research steps</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking research related to the identification and mechanistic characterization of extracellular proteases whose inhibition suppresses disease onset or progression.   

Seeking Proteases as Inhibitory Targets for Disease Treatment 

Our client is seeking novel vaccine candidates to protect against canine leptospirosis and/or leptospiruria. They aim to improve on the currently available vaccines, particularly those with immunity to one specific serovar, typically from inactivated bacteria. 
Novel vaccines should provide cross-protection against multiple leptospira serovar from the following list: Leptospira pomona; L. canicola; L. icterohaemorrhagiae; L. grippotyphosa; L. bratislava; L. australis; L. copenhageni and L. autumnalis.
<h3>Approaches of Interest:</h3>
<ul>
<li>The vaccine candidate should provide cross protection against at least two of the serovars listed, however more comprehensive protection is desirable </li>
<li>Our client is open to vaccine formulations that provide cross-protection, and could comprise: 
<ul>
<li>A recombinant or chimeric proteins (subunit), or multiple proteins that provide cross-protection in combination </li>
<li>Vectored vaccines </li>
<li>Modified-live vaccines </li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Killed (inactivated) vaccines.</li>
<li>Leptospira vaccine development in non-canine species, unless readily applicable to achieve protection in canines. </li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Cross-protection should be demonstrated in hamster challenge model, or an equivalent small animal model.</li>
<li>Validation in a canine model is desirable.</li>
</ul>
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is required, along with any relevant supplementary information e.g. relevant publications, patents. You are encouraged to outline the validation achieved for your technology, and next steps towards commercialisation. This campaign is open to submissions from academia and industry, including start‑ups. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration</h3>
Our client has commercial funding available for a collaboration, with necessary resources to progress suitable technologies from research through commercial development. Any such collaboration (including funding amount, timeline etc.) will be discussed on a case-by-case basis with selected submissions. Licensing of technologies and associated IP will also be considered.

A global company is seeking to develop novel vaccines to protect against multiple canine leptospira serovars.

Seeking Vaccine Candidates with Cross-protection Against Canine Leptospira

A publicly traded, fully integrated mid-cap biopharmaceutical company with commercial products providing aggregate &gt;$1B annual revenue is seeking therapeutic candidates for use in CNS and PNS diseases. Novel therapeutics should be a new chemical entity, ideally with a composition of matter patent filed in the last 5 years or with potential to file a composition of matter patent or other similarly meaningful patent protection. Our client is a conscientious company looking to bring assets in house and develop them to their full potential. 
Approaches of Interest:
<ul>
<li>Open to a range of neurological and psychiatric diseases </li>
<li>For neurodegenerative diseases, non-disease modifying therapeutics and treatments for management of neuropsychiatric symptoms (e.g. agitation/aggression, apathy, fatigue, psychosis) are also in scope </li>
<li>Modalities of interest include small molecules and peptides. Biologics and RNA-based therapies developed by biopharma companies are also of interest </li>
<li>Potential first-in-class therapeutics will be prioritized, potential best-in-class therapeutics will also be considered if strong rationale is provided </li>
</ul>
Out of Scope:
<ul>
<li>Therapeutics with disease-modifying action in neurodegenerative diseases or use in the following indications: nociceptive pain, MS, indications related to acute insult or injury (e.g. stroke, TBI), therapeutics with exclusive use in nicotine use disorder/ smoking cessation, diseases with less than 10,000 US patients </li>
<li>Repurposed/reformulated therapeutics </li>
<li>Diagnostics and medical devices </li>
<li>Digital therapeutics </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities that have a nominated drug candidate through to completion of Phase 1 are of interest, therapeutics that have at least in vivo validation are highest priority </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include the mechanism of action, biological rationale, a list of any validation work that has been completed, and patents that have been filed. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Partnership
Our client is open to a range of partnership opportunities, with the most appropriate structure being decided on a case-by-case basis. Example outcomes include asset acquisition and in-licensing assets, although more collaborative models are also a potential opportunity.

A publicly traded, fully integrated mid-cap biopharmaceutical company is seeking novel small molecule and peptide therapeutics for the treatment of CNS and PNS diseases.

Seeking Novel Therapeutics with Utility in CNS and PNS Indications

BSM Biotech Holding seeks innovative discovery research projects in the oncology field, to identify novel therapeutic approaches for further development. BSM expects to form new companies in collaboration with the research teams based on their technology, either by licensing deals or transfer of the technologies to the company. 
Approaches of Interest:
<ul>
<li>BSM Biotech Holding’s focus is the oncology space, in particular immuno-oncology, cancer stem cell therapy, epigenetic regulators and precision medicine based on genetic and/or molecular biomarkers. </li>
<li>Solid cancers are of high interest; however haematological cancers are also within scope.</li>
<li>All mechanisms of actions are of interest, and any modalities including mAb’s, small molecules, ADC’s, aptamers, bi/trispecific molecules and modalities regulating gene expression.</li>
</ul>
Out of Scope:
<ul>
<li>Cell therapy approaches. </li>
<li>Diagnostics (unless companion diagnostics), medical devices, nutrition, OTC products. </li>
<li>Repurposing and reformulation of therapeutics.</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Target validation and hit identification are minimum requirements. </li>
<li>Preferably in vitro validation data should be obtained, evidencing that the drug functions at the molecular/cellular level.</li>
<li>In vivo data indicative of efficacy and safety also desirable.</li>
<li>Approaches should have at least hit molecules identified and IP filed or under preparation to be filed allowing for asset protection in USA, Europe, and Japan, as a minimum.</li>
</ul>
Submission Information
Submission of 200–300-word briefs and presentations summarizing the opportunity are encouraged, along with any optional supplementary information e.g. relevant publications, patent information etc. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
BSM’s experienced management team looks to in-license discovery research projects in oncology, to fund them and spin them off into separate project-focussed companies. BSM will closely collaborate with the innovators to capitalize on their know-how and technologies. Funding and support are available on a case-by-case basis, depending on the technology and development needs.

BSM Biotech Holding seeks to develop discovery research projects in the immuno-oncology field into spin-off companies.

Seeking Novel Therapeutic Approaches in Oncology

Daiichi Sankyo, a global pharmaceutical company, is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases (ALS, AD) with high translational potential for clinical application. In the immunology domain, their interest is specifically limited to systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy. 
Approaches of Interest:
<ul>
<li>Evaluation systems and biomarkers in neurodegenerative diseases
<ul>
<li>In vitro and in vivo evaluation models with human translatability that replicate multiple aspects, such as loss of function and gain of toxic function, of TDP-43 proteinopathy in ALS alone</li>
<li>Potential biomarkers for ALS that reflect either gain-of-function (GoF) or loss-of-function (LoF) mechanisms of TDP-43, or both, identified through analyses of patient-derived samples (e.g., STMN2, UNC13A mis-splicing)</li>
<li>Potential biomarkers for AD that predict disease progression rate after onset, identified through analyses of patient-derived samples</li>
</ul>
</li>
<li>Systems for accurately predicting human immunogenicity caused by intracellularly expressed proteins from gene therapy
<ul>
<li>Excluding secreted proteins circulating in blood</li>
<li>In silico models are out of scope</li>
</ul>
</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>All stages of research are of interest for evaluations systems and biomarkers providing there is proof-of-concept</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations.

Daiichi Sankyo is seeking evaluation systems and biomarkers suitable for non-clinical studies in the fields of neurodegenerative diseases. In the immunology domain, they are interested in systems for accurately predicting human immunogenicity .

Development and Identification of Novel Evaluation Systems and Biomarkers for Gene Therapy in Neurodegenerative Diseases and Immunology

Daiichi Sankyo, a global pharmaceutical company, is seeking novel oligonucleotide-based approaches to efficiently and specifically increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Additionally, cutting-edge RNA editing techniques are also of interest.
Approaches of Interest:
<ul>
<li>Novel oligonucleotide-based technology that can control RNA expression levels or change RNA sequences e.g., dual-targeting antisense oligonucleotides (ASOs) and advanced RNA editing technologies</li>
<li>Novel technologies for efficient transport from extracellular space into cytosol, nucleus or mitochondria e.g., chemically modified oligonucleotides to enhance transport from the cytosol into the nucleus</li>
<li>Novel target-identification methods for oligonucleotide-based approaches such as ASO and RNA editing</li>
<li>Research findings on novel biological regulatory pathways or molecules that control RNA transcription, splicing, translation, or transport, with potential for future development as described in the previous three bullet points
<ul>
<li>Opportunities should demonstrate how the newly identified RNA targets could contribute to treating specific diseases</li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Packaging technologies/delivery systems (e.g. viral vectors, nanoparticles)</li>
<li>For submissions relating to ASOs, RNA editing techniques, and conventional technologies that modulate RNA by endogenous Ago2, RNase H or ADAR are out of scope</li>
<li>Submissions based on hypothetical ideas or lacking sufficient proof-of-concept</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Submissions must include, at minimum, in vitro data; in vivo data is preferred </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking novel oligonucleotide-based approaches to increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Cutting-edge RNA editing techniques are also of interest.

Innovative Oligonucleotide Strategies for Targeted RNA Expression Modulation

Certis Belchim, an expert in crop protection, is seeking novel technologies to optimize the production and reduce the application cost of its herbicide, metobromuron. Specifically, the team is interested in approaches that reduce the cost to produce the metobromuron compound or formulation improvements that reduce the dose rate of the herbicide. All approaches should be able to be scaled up to industrial quantities. In the evaluation of the proposals a feasibility study will be made. Ballpark prices of final proposal or cost reduction benchmarks with the proposed technologies are highly appreciated.
Optimization of the production process:
<ul>
<li>New chemical synthesis methods that achieve minimum gram level quantities, preferentially kg or ton level </li>
<li>Open for new production technologies, e.g. continuous flow reactors, enzymatic production, etc. </li>
<li>Improvements that make the production process more environmentally friendly are also of interest </li>
</ul>
Optimization of the formulation:
<ul>
<li>Open to a range of formulation methods, e.g. capsule suspensions, oil-based formulations, etc. </li>
<li>Adjuvants and enhancers that reduce the dose rate of the herbicide are of interest </li>
<li>Mixtures of metobromuron with other herbicides that would achieve the same effect with a reduced cost </li>
</ul>
Out of Scope:
<ul>
<li>Chemical syntheses that only achieve microgram quantities </li>
<li>Novel herbicides and methods that cannot be applied to metobromuron </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities should have at least lab-based proof of concept with a relevant example compound </li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications and benchmarks on cost improvements are highly appreciated. This campaign is open to submissions from SMEs and start-up companies. Submitters ideally have experience on industrial scale. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations. Successful submissions could lead to a joint development program with Certis Belchim to develop the approach on an industrial scale.

Certis Belchim is seeking approaches to optimize the production process and formulation of the herbicide metobromuron.

Seeking Approaches to Reduce the Application Cost of an Agrochemical Active Ingredient

Daiichi Sankyo, a global pharmaceutical company, is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors (ICIs).
<h3>Approaches of Interest:</h3>
<ul>
<li>The mechanism of resistance (MoR) is clearly defined and is tumor-intrinsic </li>
<li>The PD-1 and PD-L1 immune checkpoint pathways are of highest interest</li>
<li>Research focused on solid tumors (lung, breast and pancreatic tumors are of primary interest)</li>
<li>The MoR to ICI reflects clinical observations </li>
<li>The MoR to ICI is associated with specific patient selection biomarker </li>
</ul>
<h3>Out of Scope:</h3>
<ul>
<li>Submissions relating to blood cancers </li>
<li>Opportunities that lack a clear MoR or have tumor-extrinsic MoR </li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Opportunities from basic research to registration are in scope providing there is a clear MoR</li>
</ul>
<h3>Submission Information</h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Daiichi Sankyo is seeking research on in vivo animal models and in vitro cell/tumor tissue models exhibiting resistance to immune checkpoint inhibitors. 

Engage with world leading R&D teams

Active campaigns

ico